Details of Disease

General Information of Disease (ID: DISJSGBZ)

• Disease Name: Peptic esophagitis
• Synonyms: reflux esophagitis; peptic esophagitis; peptic reflux disease; reflux oesophagitis
• Definition: Inflammation of the esophagus that is caused by the reflux of gastric juice with contents of the stomach and duodenum.
• Disease Hierarchy:
  DISHVC9B: Esophagitis
  DISL8XZI: Peptic ulcer
  DISNUPWL: Esophageal ulcer
  DISJSGBZ: Peptic esophagitis
• Disease Identifiers:
  MONDO ID: MONDO_0006896
  MESH ID: D004942
  UMLS CUI: C0014869
  MedGen ID: 5028

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Esomeprazole	DM7BN0X	Approved	Small molecular drug	[1]
Famotidine	DMRL3AB	Approved	Small molecular drug	[2]
Nizatidine	DMGFV3Z	Approved	Small molecular drug	[3]
Omeprazole	DM471KJ	Approved	Small molecular drug	[4]

Molecular Interaction Atlas (MIA) of This Disease

This Disease Is Related to 11 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
ATP4A	TTF1QVM	Limited	Biomarker	[5]
CYP2C19	TTZ58XG	Limited	Genetic Variation	[6]
HRH2	TTQHJ1K	Limited	Biomarker	[7]
BMP4	TTD3BSX	Strong	Biomarker	[8]
CCL5	TT9DWLC	Strong	Biomarker	[9]
CLDN4	TTMTS9H	Strong	Biomarker	[10]
F11R	TT3C8EG	Strong	Therapeutic	[11]
IL13	TT0GVCH	Strong	Biomarker	[9]
IL5	TTPREZD	Strong	Biomarker	[9]
PSMB9	TTOUSTQ	Strong	Biomarker	[12]
PTGES	TTYLQ8V	Strong	Biomarker	[13]

This Disease Is Related to 1 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ATP12A	DT5NLZA	Limited	Biomarker	[5]

This Disease Is Related to 6 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
ECI1	OTRQTK84	Limited	Biomarker	[14]
IL36RN	OT5CO95A	Limited	Biomarker	[15]
MLN	OTBZ5SE5	Limited	Biomarker	[16]
CLDN3	OT71MN9S	Strong	Biomarker	[17]
MYO9B	OTQ94R5K	Strong	Altered Expression	[18]
TJP1	OTBDCUPK	Strong	Biomarker	[19]

References

• [1] Esomeprazole FDA Label
• [2] Famotidine FDA Label
• [3] Nizatidine FDA Label
• [4] Omeprazole FDA Label
• [5] Similarities and differences among eosinophilic esophagitis, proton-pump inhibitor-responsive esophageal eosinophilia, and reflux esophagitis: comparisons of clinical, endoscopic, and histopathological findings in Japanese patients.J Gastroenterol. 2017 Feb;52(2):203-210. doi: 10.1007/s00535-016-1213-1. Epub 2016 Apr 23.
• [6] Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.J Gastroenterol Hepatol. 2016 Apr;31(4):716-26. doi: 10.1111/jgh.13233.
• [7] Pharmacological control of gastric acid secretion for the treatment of acid-related peptic disease: past, present, and future.Pharmacol Ther. 2003 Apr;98(1):109-27. doi: 10.1016/s0163-7258(03)00015-9.
• [8] Bone morphogenetic protein 4 expressed in esophagitis induces a columnar phenotype in esophageal squamous cells.Gastroenterology. 2007 Jun;132(7):2412-21. doi: 10.1053/j.gastro.2007.03.026. Epub 2007 Mar 19.
• [9] A novel rat model to determine interaction between reflux oesophagitis and bronchial asthma.Gut. 2008 May;57(5):575-81. doi: 10.1136/gut.2007.138461. Epub 2008 Jan 25.
• [10] Altered localization and expression of tight-junction proteins in a rat model with chronic acid reflux esophagitis.J Gastroenterol. 2005 Aug;40(8):781-90. doi: 10.1007/s00535-005-1628-6.
• [11] Slit diaphragms contain tight junction proteins.J Am Soc Nephrol. 2009 Jul;20(7):1491-503. doi: 10.1681/ASN.2008101117. Epub 2009 May 28.
• [12] Effects of sterigmatocystin on esophageal epithelium and experimental reflux esophagitis in rats.Mol Med Rep. 2013 Oct;8(4):1043-8. doi: 10.3892/mmr.2013.1631. Epub 2013 Aug 14.
• [13] Roles of cyclooxygenase 2 and microsomal prostaglandin E synthase 1 in rat acid reflux oesophagitis.Gut. 2006 Apr;55(4):450-6. doi: 10.1136/gut.2005.081943. Epub 2005 Oct 6.
• [14] Impact of reflux esophagitis on the esophageal function before and after laparoscopic fundoplication.Esophagus. 2018 Oct;15(4):224-230. doi: 10.1007/s10388-018-0618-8. Epub 2018 Apr 26.
• [15] Association between interleukin-1beta-511C/T polymorphism and reflux esophagitis in Japan.J Gastroenterol. 2005 Sep;40(9):873-7. doi: 10.1007/s00535-005-1672-2.
• [16] Associations between the severity of reflux esophagitis in children and changes in oxidative stress, serum inflammation, vasoactive intestinal peptide and motilin.Exp Ther Med. 2019 Nov;18(5):3509-3513. doi: 10.3892/etm.2019.7978. Epub 2019 Sep 6.
• [17] Dissociation and dispersion of claudin-3 from the tight junction could be one of the most sensitive indicators of reflux esophagitis in a rat model of the disease.J Gastroenterol. 2011 May;46(5):629-38. doi: 10.1007/s00535-011-0390-1. Epub 2011 Mar 5.
• [18] Myo9B is associated with an increased risk of Barrett's esophagus and esophageal adenocarcinoma.Scand J Gastroenterol. 2012 Dec;47(12):1422-8. doi: 10.3109/00365521.2012.722673. Epub 2012 Sep 7.
• [19] Interleukin-6, desmosome and tight junction protein expression levels in reflux esophagitis-affected mucosa.World J Gastroenterol. 2009 Aug 7;15(29):3621-30. doi: 10.3748/wjg.15.3621.